Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology-Reference-Cited by-同舟云学术

Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology

Published:2024-01-09 Issue:2 Volume:15 Page:189-196
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

He Liqi¹,Zhang Meng Yao¹^ORCID,Cox Matthew¹,Zhang Qian¹,Donnell Andrew F.²^ORCID,Zhang Yong²^ORCID,Tarby Christine²,Gill Patrice²,Subbaiah Murugaiah A. M.³^ORCID,Ramar Thangeswaran³,Reddy Maheswara³,Puttapaka Vijaya³,Li Yi-Xin¹,Sivaprakasam Prasanna²^ORCID,Critton David²,Mulligan Dawn²,Xie Chunshan²,Ramakrishnan Radha²,Nagar Jignesh³,Dudhgaonkar Shailesh³,Murtaza Anwar²,Oderinde Martins S.²^ORCID,Schieven Gary L.²,Mathur Arvind²,Gavai Ashvinikumar V.²^ORCID,Vite Gregory²,Gangwar Sanjeev¹,Poudel Yam B.¹^ORCID

Affiliation:

1. Research and Development, Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States

2. Research and Development, Bristol Myers Squibb, Princeton, New Jersey 08543, United States

3. Biocon Bristol Myers Squibb R&D Centre, Bangalore 560099, India

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.3c00456

Reference31 articles.

1. Modes of action of TLR7 agonists in cancer therapy

2. Anti-tumor Activity of Toll-Like Receptor 7 Agonists

3. Targeting Toll-like receptors: emerging therapeutics?

4. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants

5. TLR7 and TLR8 as targets in cancer therapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and Evaluation of TLR-Targeted Immune Agonists;Journal of Medicinal Chemistry;2024-09-05

2. Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology;ACS Medicinal Chemistry Letters;2024-01-08